PLATELET-ACTIVATING FACTOR ANTAGONISTS IN BRONCHIAL ASTHMA

[1]  J. Barberà,et al.  The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma. , 1998, American journal of respiratory and critical care medicine.

[2]  C. Ezeamuzie,et al.  Effects of Some Anti-Asthma Drugs on Human Eosinophil Superoxide Anions Release and Degranulation , 1998, International Archives of Allergy and Immunology.

[3]  Y. Ouchi,et al.  Airway responsiveness in transgenic mice overexpressing platelet-activating factor receptor. Roles of thromboxanes and leukotrienes. , 1997, American journal of respiratory and critical care medicine.

[4]  K. Waku,et al.  Comparison of platelet-activating factor receptor mRNA levels in peripheral blood eosinophils from normal subjects and atopic asthmatic patients. , 1997, International archives of allergy and immunology.

[5]  S. Kohno,et al.  Eosinophil chemotaxis induced by several biologically active substances and the effects of apafant on it in vitro. , 1997, Arzneimittel-Forschung.

[6]  J. Barberà,et al.  Inhibition of PAF-induced gas exchange defects by beta-adrenergic agonists in mild asthma is not due to bronchodilation. , 1997, American journal of respiratory and critical care medicine.

[7]  P. Barnes,et al.  Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses. , 1997, American journal of respiratory and critical care medicine.

[8]  M. Triggiani,et al.  Characterization of platelet-activating factor acetylhydrolase in human bronchoalveolar lavage. , 1997, American journal of respiratory and critical care medicine.

[9]  A. Sampson,et al.  The effect of inhaled leukotriene B4 in normal and in asthmatic subjects. , 1997, American journal of respiratory and critical care medicine.

[10]  R. Louis,et al.  Acute bronchial obstruction following inhalation of PAF in asthmatic and normal subjects: comparison with methacholine. , 1996, The European respiratory journal.

[11]  M. Yamakido,et al.  Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. , 1995, American journal of respiratory and critical care medicine.

[12]  K. Chung,et al.  Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. , 1995, American journal of respiratory and critical care medicine.

[13]  P. Franchimont,et al.  Changes in bronchial responsiveness, circulating leucocytes and ex vivo cytokine production by blood monocytes after PAF inhalation in allergic asthmatics. , 1995, The European respiratory journal.

[14]  R. Louis,et al.  Acute bronchial and hematologic effects following inhalation of a single dose of PAF. Comparison between asthmatics and normal subjects. , 1994, Chest.

[15]  R. Townley,et al.  The effect of RP 59227, a platelet-activating factor antagonist, against antigen challenge and eosinophil and neutrophil chemotaxis in asthmatics. , 1994, Journal of lipid mediators and cell signalling.

[16]  J. Barberà,et al.  Inhaled platelet-activating factor worsens gas exchange in mild asthma. , 1994, American journal of respiratory and critical care medicine.

[17]  K. Chung,et al.  Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans. , 1994, American journal of respiratory and critical care medicine.

[18]  W. Henderson,et al.  Inflammatory effects of ozone in the upper airways of subjects with asthma. , 1994, American journal of respiratory and critical care medicine.

[19]  P. Calverley,et al.  The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. , 1994, American journal of respiratory and critical care medicine.

[20]  M. Kurosawa,et al.  Increased levels of blood platelet‐activating factor in bronchial asthmatic patients with active symptoms , 1994, Allergy.

[21]  E. Israel,et al.  The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. , 1993, The American review of respiratory disease.

[22]  R. Louis,et al.  No increase in plasma histamine during PAF-induced airway obstruction in allergic asthmatics. , 1993, Chest.

[23]  K. Patel,et al.  Effect of cetirizine, a potent H1 antagonist, on platelet activating factor induced bronchoconstriction in asthma , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  P. O'Byrne,et al.  Effect of a platelet activating factor antagonist, WEB 2086, on allergen induced asthmatic responses. , 1993, Thorax.

[25]  H. J. Mengelers,et al.  Occupancy of platelet receptors for platelet-activating factor in asthmatic patients during an allergen-induced bronchoconstrictive reaction. , 1993, Journal of lipid mediators.

[26]  G. Zimmerman,et al.  Platelet-activating factor: a phospholipid autacoid with diverse actions. , 1993, Journal of lipid research.

[27]  K. Hsieh,et al.  Increased plasma platelet-activating factor in children with acute asthmatic attacks and decreased in vivo and in vitro production of platelet-activating factor after immunotherapy. , 1993, The Journal of allergy and clinical immunology.

[28]  M. Billah,et al.  Differential plasma duration of antiplatelet‐activating factor and antihistamine activities of oral Sch 37370 in humans , 1992, Clinical pharmacology and therapeutics.

[29]  U. Schauer,et al.  Enhanced production of platelet activating factor by peripheral granulocytes from children with asthma , 1992, Allergy.

[30]  S. Shukla.  Platelet‐activating factor receptor and signal transduction mechanisms 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  T. Lee,et al.  Mediator concentrations in bronchoalveolar lavage fluid of patients with mild asymptomatic bronchial asthma. , 1992, The European respiratory journal.

[32]  J. Sugatani,et al.  Release of newly synthesized platelet-activating factor (PAF) from human polymorphonuclear leukocytes under in vivo conditions. Contribution of PAF-releasing factor in serum. , 1992, Journal of immunology.

[33]  H. Bito,et al.  Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. , 1991, The Journal of biological chemistry.

[34]  E. Prossnitz,et al.  Characterization of a human cDNA that encodes a functional receptor for platelet activating factor. , 1991, Biochemical and biophysical research communications.

[35]  D. Agrawal,et al.  Terfenadine effect on the bronchoconstriction, dermal response, and leukopenia induced by platelet-activating factor. , 1991, Chest.

[36]  D. Agrawal,et al.  Platelet-activating factor induces nonspecific desensitization to bronchodilators in guinea pigs. , 1991, The Journal of pharmacology and experimental therapeutics.

[37]  C. Dollery,et al.  Inhaled PAF stimulates leukotriene and thromboxane A2 production in humans. , 1991, Journal of applied physiology.

[38]  P. Piper,et al.  Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man. , 1991, Thorax.

[39]  K. Hsieh.  Effects of PAF antagonist, BN52021, on the PAF-, methacholine-, and allergen-induced bronchoconstriction in asthmatic children. , 1991, Chest.

[40]  M. Chan-yeung,et al.  The release of platelet-activating factor into plasma during allergen-induced bronchoconstriction. , 1991, The Journal of allergy and clinical immunology.

[41]  Paul H. Rubin,et al.  Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. , 1991, Thorax.

[42]  Takao Shimizu,et al.  Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung , 1991, Nature.

[43]  Paul H. Rubin,et al.  The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. , 1990, The New England journal of medicine.

[44]  D. Agrawal,et al.  Effect of PAF-acether inhalation on nonspecific bronchial reactivity and adrenergic response in normal and asthmatic subjects. , 1990, Chest.

[45]  M. Record,et al.  PAF-acether transfer activity in HL-60 cells is induced during differentiation. , 1990, Biochemical and biophysical research communications.

[46]  L. Smith,et al.  Effects of inhaled leukotriene D4 and platelet-activating factor on airway reactivity in normal subjects. , 1990, The American review of respiratory disease.

[47]  D. Hendrick,et al.  Platelet-activating factor in bronchoalveolar lavage fluid from asthmatic subjects. , 1990, The European respiratory journal.

[48]  H. Heuer,et al.  Inhibitory effects of the new PAF acether antagonist WEB‐2086 on pharmacologic changes induced by PAF inhalation in human beings , 1990, Clinical pharmacology and therapeutics.

[49]  F. Chilton,et al.  Release of platelet-activating factor and the metabolism of leukotriene B4 by the human neutrophil when studied in a cell superfusion model. , 1989, Journal of immunology.

[50]  D. Agrawal,et al.  Effect of platelet-activating factor inhalation on nonspecific bronchial reactivity in man. , 1989, Chest.

[51]  J. Benveniste,et al.  Regulation of cellular retention of paf-acether by extracellular pH and cell concentration. , 1989, Biochimica et biophysica acta.

[52]  P. Barnes,et al.  Effect of theophylline on airway responses to inhaled platelet-activating factor in man. , 1989, The European respiratory journal.

[53]  K. Chung,et al.  Effects of salbutamol on bronchoconstriction, bronchial hyperresponsiveness, and leucocyte responses induced by platelet activating factor in man. , 1989, Thorax.

[54]  K. Chung,et al.  Effects of platelet activating factor on airway calibre, airway responsiveness, and circulating cells in asthmatic subjects. , 1989, Thorax.

[55]  D. Agrawal,et al.  Leukotriene C4 production from human eosinophils in vitro. Role of eosinophil chemotactic factors on eosinophil activation. , 1988, Journal of immunology.

[56]  J. O'flaherty,et al.  Evidence for protein-catalyzed transfer of platelet activating factor by macrophage cytosol. , 1988, Biochimica et biophysica acta.

[57]  R. Patterson,et al.  The bronchoconstrictor properties of platelet-activating factor in humans. , 1987, The American review of respiratory disease.

[58]  G. Zimmerman,et al.  Production of platelet-activating factor by stimulated human polymorphonuclear leukocytes. Correlation of synthesis with release, functional events, and leukotriene B4 metabolism. , 1987, Journal of immunology.

[59]  D. Agrawal,et al.  Effects of platelet activating factor on the chemotaxis of normodense eosinophils from normal subjects. , 1987, Biochemical and biophysical research communications.

[60]  L. Koenderman,et al.  Platelet-activating factor (PAF-acether) induced leukotriene C4 formation and luminol dependent chemiluminescence by human eosinophils. , 1986, Pharmacological research communications.

[61]  F. Cuss,et al.  EFFECTS OF INHALED PLATELET ACTIVATING FACTOR ON PULMONARY FUNCTION AND BRONCHIAL RESPONSIVENESS IN MAN , 1986, The Lancet.

[62]  G. Zimmerman,et al.  Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate. , 1985, The Journal of clinical investigation.

[63]  M. Oda,et al.  Molecular species of platelet-activating factor generated by human neutrophils challenged with ionophore A23187. , 1985, Journal of immunology.

[64]  J. C. Ludwig,et al.  Modulation of platelet-activating factor (PAF) synthesis and release from human polymorphonuclear leukocytes (PMN): role of extracellular albumin. , 1984, Archives of biochemistry and biophysics.

[65]  N. Voelkel,et al.  Nonimmunological production of leukotrienes induced by platelet-activating factor. , 1982, Science.

[66]  F. Snyder,et al.  Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. , 1979, Biochemical and biophysical research communications.

[67]  D. Hanahan,et al.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). , 1979, The Journal of biological chemistry.

[68]  P. Henson,et al.  LEUKOCYTE-DEPENDENT HISTAMINE RELEASE FROM RABBIT PLATELETS THE ROLE OF IGE, BASOPHILS, AND A PLATELET-ACTIVATING FACTOR , 1972 .

[69]  N. Zvaifler,et al.  Antigen Induced Histamine Release from Platelets of Rabbits Producing Homologous PGA Antibody. , 1966, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[70]  M. Kagoshima,et al.  Suppressive effects of Y-24180, a long-acting antagonist for platelet-activating factor, on allergic pulmonary eosinophilia in mice. , 1997, Japanese journal of pharmacology.

[71]  T. Miyamoto,et al.  Effect of a potent platelet-activating factor antagonist, WEB-2086, on asthma. A multicenter, double-blind placebo-controlled study in Japan. , 1996, Advances in experimental medicine and biology.

[72]  J. Barberà,et al.  Platelet-activating factor causes ventilation-perfusion mismatch in humans. , 1994, The Journal of clinical investigation.

[73]  K. Chung,et al.  Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219. , 1993, The American review of respiratory disease.

[74]  M. Nagata,et al.  The evidence of platelet activation in bronchial asthma. , 1993, The Journal of allergy and clinical immunology.

[75]  K. P. Hui,et al.  Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen. , 1993, The American review of respiratory disease.

[76]  P. Leuenberger,et al.  Platelet-activating factor does not induce bronchial hyperreactivity in nonasthmatic subjects. , 1992, Respiration; international review of thoracic diseases.

[77]  P. Howarth,et al.  Effect of inhaled platelet-activating factor on bronchial inflammation in atopic non-asthmatic subjects. , 1992, International archives of allergy and immunology.

[78]  R. Patterson,et al.  Mechanism of platelet activating factor-induced bronchoconstriction in humans. , 1988, The American review of respiratory disease.